Sort   by:  
 Page size 
UnknownSLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium.
Not available
S-EPMC3075571 | biostudies-literature
UnknownClinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Not available
S-EPMC9151663 | biostudies-literature
UnknownV-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
Not available
S-EPMC12418821 | biostudies-literature
UnknownFollow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Not available
S-EPMC9197557 | biostudies-literature
UnknownOutcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Not available
S-EPMC10189888 | biostudies-literature
UnknownQuizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Not available
S-EPMC8152787 | biostudies-literature
UnknownManagement of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Not available
S-EPMC4511225 | biostudies-literature
UnknownLow-fat, increased fruit, vegetable, and grain dietary pattern, fractures, and bone mineral density: the Women's Health Initiative Dietary Modification Trial.
Not available
S-EPMC2682999 | biostudies-literature
Sort   by:  
 Page size